Efficacy and safety of rituximab biosimilars or reference product as first‐line treatment in patients with low‐tumour‐burden follicular lymphoma: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Efficacy and safety of rituximab biosimilars or reference product as first‐line treatment in patients with low‐tumour‐burden follicular lymphoma: A systematic review and meta‐analysis

Published:2022-11-07 Issue:12 Volume:47 Page:1923-1931
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:Clinical Pharmacy Therapeu

Author:

Yang Liu¹²,Zheng Zhiwei³^ORCID,Li Na¹²,Zheng Bin¹²,Liu Maobai¹²,Cai Hongfu¹²^ORCID

Affiliation:

1. Department of Pharmacy Fujian Medical University Union Hospital Fuzhou China

2. The School of Pharmacy Fujian Medical University Fuzhou China

3. Department of Pharmacy Cancer Hospital of Shantou University Medical College Shantou China

Funder

Fujian Provincial Department of Science and Technology

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13799

Reference21 articles.

1. American Cancer Society. Accessed March 8 2022.https://www.cancer.org/content/dam/cancer‐org/research/cancer‐facts‐and‐statistics/annual‐cancer‐facts‐and‐fgures/2020/cancer‐facts‐and‐fgures‐2020.pdf

2. Indolent lymphoma: the pathologist’s viewpoint

3. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

4. Hofmann‐La Roche Ltd. Accessed March 7 2022.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000165/WC500025821.pdf

5. Genentech Inc. Accessed March 7 2022.http://www.gene.com/download/pdf/rituxan_prescribing.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in treatment of nodal and gastrointestinal follicular lymphoma;World Journal of Gastroenterology;2023-06-21